FGFR2, fibroblast growth factor receptor 2, 2263

N. diseases: 731; N. variants: 141
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE Fibroblast growth factor receptor 2 (FGFR2) might have an important role in the pathogenesis and biology of cholangiocarcinoma (CCA). 31351075 2019
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 GeneticVariation disease BEFREE Herein, we report the first case with cholangiocarcinoma harboring <i>FGFR2-BICC1</i> who is sensitive to sorafenib therapy. 31807010 2019
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE The current review comprehensively focuses on the role of FGFR2 inhibition either alone or in combination with other targeted therapy that act on down-stream and alternate kinase pathways in cholangiocarcinoma. 31255945 2019
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. 30067876 2019
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 GeneticVariation disease BEFREE For example, IDH catalytic site mutations and constitutively active FGFR2 fusion genes are predominantly identified in iCCA, whereas KRAS mutations and PRKACB fusions genes are identified in pCCA and dCCA. 28844952 2018
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 GeneticVariation disease BEFREE Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. 29182496 2018
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. 28034880 2017
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE Using this PDX model, we confirmed the ability of the FGFR inhibitors, ponatinib, dovitinib and BGJ398, to modulate FGFR signaling, inhibit cell proliferation and induce cell apoptosis in cholangiocarcinoma tumors harboring FGFR2 fusions. 27216979 2016
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease CTD_human Genomic spectra of biliary tract cancer. 26258846 2015
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. 25763789 2015
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 Biomarker disease BEFREE Histologically, cholangiocarcinomas with FGFR2 translocations displayed prominent intraductal growth (62%) or anastomosing tubular glands with desmoplasia (38%). 24837095 2014
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma
0.400 GeneticVariation disease BEFREE Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. 23558953 2013